crispr/cas9 mediated disruption of the swedish app allele as a therapeutic approach for early-onset alzheimer’s disease

Clicks: 326
ID: 143223
2018
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #9 of 77 articles by views in coordination chemistry reviews

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
The APPswe (Swedish) mutation in the amyloid precursor protein (APP) gene causes dominantly inherited Alzheimer’s disease (AD) as a result of increased β-secretase cleavage of the amyloid-β (Aβ) precursor protein. This leads to abnormally high Aβ levels, not only in brain but also in peripheral tissues of mutation carriers. Here, we selectively disrupted the human mutant APPSW allele using CRISPR. By applying CRISPR/Cas9 from Streptococcus pyogenes, we generated allele-specific deletions of either APPSW or APPWT. As measured by ELISA, conditioned media of targeted patient-derived fibroblasts displayed an approximate 60% reduction in secreted Aβ. Next, coding sequences for the APPSW-specific guide RNA (gRNA) and Cas9 were packaged into separate adeno-associated viral (AAV) vectors. Site-specific indel formation was achieved both in primary neurons isolated from APPSW transgenic mouse embryos (Tg2576) and after co-injection of these vectors into hippocampus of adult mice. Taken together, we here present proof-of-concept data that CRISPR/Cas9 can selectively disrupt the APPSW allele both ex vivo and in vivo—and thereby decrease pathogenic Aβ. Hence, this system may have the potential to be developed as a tool for gene therapy against AD caused by APPswe and other point mutations associated with increased Aβ.
Reference Key
gyrgy2018molecularcrispr/cas9 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Bence György;Camilla Lööv;Mikołaj P. Zaborowski;Shuko Takeda;Benjamin P. Kleinstiver;Caitlin Commins;Ksenia Kastanenka;Dakai Mu;Adrienn Volak;Vilmantas Giedraitis;Lars Lannfelt;Casey A. Maguire;J. Keith Joung;Bradley T. Hyman;Xandra O. Breakefield;Martin Ingelsson
Journal coordination chemistry reviews
Year 2018
DOI
10.1016/j.omtn.2018.03.007
URL
http://www.sciencedirect.com/science/article/pii/S2162253118300374
Keywords
genome editing alzheimer's disease adeno-associated virus crispr pharmacology amyloid-βtherapeutics

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.